Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal, disabling disease, commonly associated with skin psoriasis, and estimated to affect up to 42% of the approximately 7.5 million people in the United States with psoriasis. There remains an ongoing challenge among clinicians to diagnose and treat patients, as well as to stay abreast of optimal treatment strategies. In this educational program, the latest biologic treatment recommendations are reviewed, as well as clinical trial results for novel emerging therapies. Clinician-patient communication examples are shared on how to engage patients in their management, along with best-practice, stepwise recommendations to achieve remission with minimal or low disease activity with the use of appropriate assessment and screening tools to improve overall outcomes in the PsA patient.

Please join Dr. Husni and Dr. Merola as they share their insights on how to make an early and accurate diagnosis for PsA and implement therapeutic strategies.

Enter your information to begin.

Content Areas

  • Psychosocial burden of PsA
  • Classification criteria
  • Clinical presentation of PsA
  • Comorbidities associated with PsA
  • Interdisciplinary communication
  • Clinical domains of PsA
  • Approved biologic treatment strategies
  • Disease activity measures for PsA

faculty

M. Elaine Husni, MD, MPH
Vice Chair, Rheumatology
Director, Arthritis and Musculoskeletal Center
Cleveland Clinic
Assistant Professor
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Joseph F. Merola, MD, MMSc
Assistant Professor, Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Director, Center for Skin and Related Musculoskeletal Diseases
Associate Program Director, Harvard Combined Internal Medicine-Dermatology Residency Training Program
Brigham and Women's Hospital
Boston, Massachusetts

Cme credit

Available Credit: 1.50 AMA PRA Category 1 Credits™.
1.50 ANCC Contact Hours
Opens: October 09, 2018
Expires: October 08, 2019
Target Audience: Rheumatologists
Dermatologists
Primary Care Physicians
Physician Assistants
Nurses
Nurse Practitioners
Other Health Care Providers
This activity is supported by an independent educational grant from Celgene.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.